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Hyaluronan abrogates imatinib-
induced senescence in chronic 
myeloid leukemia cell lines
silvina Lompardía1,2, Mariángeles Díaz2, Matías pibuel1,2, Daniela papademetrio1,2, 
Daniela poodts1, Cintia Mihalez1,2, Élida Álvarez1,2 & silvia Hajos1,2
Hyaluronan (HA) is the main glycosaminoglycan of the extracellular matrix. CD44 is the most important 
HA receptor, and both have been associated with poor prognosis in cancer. Chronic myeloid leukemia 
(CML) is characterized by the presence of a constitutively activated tyrosine kinase (Breakpoint Cluster 
Region - Abelson murine leukemia viral oncogene homolog1, BCR-ABL). It is mainly treated with BCR-
ABL inhibitors, such as imatinib. However, the selection of resistant cells leads to treatment failure. The 
aim of this work was to determine the capacity of HA (high molecular weight) to counteract the effect of 
imatinib in human CML cell lines (K562 and Kv562). We demonstrated that imatinib decreased HA levels 
and the surface expression of CD44 in both cell lines. Furthermore, HA abrogated the anti-proliferative 
and pro-senescent effect of Imatinib without modifying the imatinib-induced apoptosis. Moreover, 
the inhibition of HA synthesis with 4-methylumbelliferone enhanced the anti-proliferative effect of 
imatinib. These results suggest that Imatinib-induced senescence would depend on the reduction in HA 
levels, describing, for the first time, the role of HA in the development of resistance to imatinib. These 
findings show that low levels of HA are crucial for an effective therapy with imatinib in CML.
It is known that the tumor microenvironment characteristics are crucial for the progression of several malig-
nancies1. One of the main components of extracellular matrix is hyaluronan (HA), a lineal non-sulfated glycos-
aminoglycan consisting of repetitive units of D-glucuronic acid and N-acetyl-D-glucosamine. HA plays many 
physiological roles, such as the organization and maintenance of the tissue architecture, wound healing, leukocyte 
trafficking, and cell growth and differentiation, among others. HA also seems to play a role in stem cells niches 
where it would protect these cells from DNA damage. This function is accomplished through its antioxidant 
action and the activation of efflux pumps that extrude genotoxic compounds2,3.
The amount of HA in a tissue results from a complex balance between its synthesis by glycosyltransferases 
(hyaluronan synthases, HAS), its internalization via surface receptors and its degradation mediated by hyaluroni-
dases (HYALs)2,4–6. Changes occurring in any of these processes lead to an imbalance in the quantity and quality 
of HA. It has been demonstrated that low HA levels in bone marrow inhibit the capacity of the cellular microen-
vironment to maintain a normal hematopoiesis7,8. In several solid tumors, the amount of HA exceeds the phys-
iological levels enhancing cell proliferation, migration, apoptosis evasion and multidrug resistance (MDR)9–13. 
These effects are exerted through the activation of several signaling pathways, such as phosphoinositide 3-kinase 
(PI3K)/protein kinase B (Akt) and Mitogen-Activated Protein Kinases (MAPK), as a result from the interaction 
of HA with its receptors, being CD44 the most studied one in oncology14.
However, little is it known about the role of HA on chronic myeloid leukemia (CML) progression. CML is 
a myeloproliferative syndrome characterized by the presence of the Philadelphia chromosome (Ph+), which 
encodes a constitutively activated tyrosine kinase (Breakpoint Cluster Region - Abelson murine leukemia viral 
oncogene homolog 1, BCR-ABL)15–17. The first line treatment for CML consists of BCR-ABL inhibitors such as 
imatinib, nilotinib and dasatinib15,16. Although imatinib is a highly effective drug for the treatment of CML, drug 
resistance may occur, leading to therapeutic failure. The identification of the molecules involved in resistance 
phenomena is then of great value for the development of novel effective chemotherapeutic agents.
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It has recently been demonstrated that low levels of CD44 are associated with a better therapeutic response to 
nilotinib in different models of CML18. We have previously demonstrated that human CML cell lines synthesize 
HA that is crucial to prevent cells from undergoing senescence and resist the cytostatic effect of vincristine19. In 
addition, we have shown that HA oligomers and 4-methylumbelliferone (4MU) enhance the effect of imatinib 
on CML cell lines20,21. Due to their small size, HA oligomers bind HA receptors without activating them10, while 
4MU inhibits the HA synthesis by depleting the levels of UDP-glucuronic acid (substrate of HAS)22.
One of the most commonly used in vitro CML models is the K562 human cell line23,24. In these cells, the 
anti-proliferative effect of imatinib is mediated by the induction of apoptosis and senescence21,25. These bio-
logical processes are two of the most important mechanisms of tumor suppression. Apoptosis is a type of pro-
grammed cell death26, while senescence is a terminal differentiation stage characterized by an irreversible cell 
cycle arrest27–31.
Multiple factors are known to contribute to the development of chemoresistance, being the extracellular 
matrix a key component of the tumor microenvironment. We hypothesize that the HA present in such microen-
vironment enhances MDR favoring leukemia progression. The aim of this work was to determine whether high 
molecular weight HA abrogates the effect of imatinib in human CML cell lines, describing for the first time the 
role of HA on imatinib resistance. The findings presented herein highlight the importance of reducing the levels 
of HA for an effective therapy with imatinib in CML.
Results
Imatinib reduces BCR-ABL and HA levels, as well as CD44 surface expression. The capacity of 
imatinib to modulate BCR-ABL, HA and CD44 levels was first analyzed. BCR-ABL levels were evaluated by west-
ern blot (WB), HA levels were analyzed by ELISA and the expression of CD44 by flow cytometry (FC).
Figure 1A shows that HA did not modify the expression of BCR-ABL, while imatinib decreased the expression 
levels with respect to the baseline condition in K562 and Kv562 cells. Moreover, in cells co-treated with imatinib 
and HA, the levels of BCR-ABL were similar to those obtained with imatinib alone. Figure 1B shows that HA 
levels in the culture supernatant of imatinib-treated cells were diminished, as compared to untreated control 
cells. However, such decrement was of a smaller magnitude than the one obtained with 4MU. It is noteworthy that 
we have previously demonstrated that 4MU completely inhibits the synthesis of HA19. Figure 1C shows that the 
treatment with imatinib decreased the surface expression of CD44 in both cell lines without modifying the total 
expression levels of this marker, suggesting that this drug induces the internalization of this receptor. The U937 
cell line was used as a negative control for BCR-ABL and a positive control for CD4432,33.
Thus, imatinib reduced HA levels and the surface expression of CD44, suggesting that BCR-ABL would favor 
the accumulation of HA in the culture supernatant and of CD44 on the cell surface.
HA abrogates the anti-proliferative effect of imatinib without modifying imatinib-induced 
apoptosis. Considering that imatinib induced a partial decrease of HA levels, it was interesting to evaluate 
if such reduction was necessary for the drug to exert its anti-proliferative and pro-apoptotic effects. For that 
purpose, both cell lines were treated with either imatinib, HA or a combination of both to determine cell prolifer-
ation rates by the tritiated thymidine ([3H]TdR) uptake assay and the apoptosis levels by the DNA fragmentation, 
annexin-PE/7AAD and subG1 peak assays.
Figure 2A shows that, unlike imatinib, the treatment with HA enhanced the proliferative capacity of both cell 
lines. HA counteracted the anti-proliferative effect of imatinib on K562 cells, at all the drug doses tested. However, 
in Kv562 cells, this phenomenon was only observed with the combination of HA with the lowest dose of imatinib 
(0.5 µM).
It was also interesting to evaluate the effect of HA on imatinib-induced apoptosis in both cell lines. HA 
modified neither the percentage of DNA fragmentation (Fig. 2B), nor the number of annexin-PE positive cells 
(Fig. 2C), nor the subG1 peak (Fig. 2D), as compared to control cells. Conversely, the treatment with 0.5 and 2 µM 
imatinib increased such parameters in K562 and Kv562 cells, respectively. However, the co-treatment of cells with 
HA and imatinib did not modify the apoptosis levels, as compared with imatinib alone in both cell lines.
These results suggest that HA would abrogate part of the therapeutic effect of imatinib by suppress-
ing its anti-proliferative effect. However, HA does not seem to be involved in the mechanism of evasion from 
imatinib-induced apoptosis.
HA prevents imatinib-induced senescence. We have previously described that HA prevents the induc-
tion of senescence in both cell lines19 and that it suppresses the anti-proliferative effect of imatinib. We then eval-
uated if HA was able to abrogate imatinib-induced senescence. To that end, the activity of senescence-associated 
β-galactosidase (SA-β-gal) and the presence of senescence-associated heterochromatin foci (SAHF) were 
determined.
As shown in Fig. 3, HA modified neither the percentage of SA-β-gal positive cells nor the presence of SAHF 
with respect to baseline conditions in both cell lines. Contrarily, imatinib at 0.25 and 0.5 µM increased such 
parameters in both cell lines. However, the treatment with 2 µM imatinib did not induce senescence in Kv562 
cells. For all doses of imatinib that induced senescence, the addition of HA prevented the appearance of SA-β-gal 
positive cells (Fig. 3A) and SAHF (Fig. 3B), thus restoring the baseline conditions.
These results suggest that HA abrogates imatinib-induced senescence and that HA would be involved in the 
development of imatinib resistance.
HA abrogates the effect of imatinib on the pAkt/Akt ratio but not on the pERK/ERK ratio. 
Knowing that the PI3K/Akt and MAPK pathways are crucial for leukemic cell growth34 and that they are 
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modulated by HA, it was interesting to assess if such signaling pathways participate in the effects described above. 
Therefore, WB assays were performed to determine pAkt/Akt and pERK/ERK ratios after the treatment with 
either HA, Imatinib or combinations of them.
Figure 4A shows that HA increased the pAkt/Akt ratio in both cell lines, while this ratio was found to be 
decreased upon treatment with imatinib. The co-treatment with HA and imatinib restored the baseline conditions 
in both K562 and Kv562 cells. The biological replicates are shown in Supplementary Fig. S1.
Figure 4B shows that HA augmented the pERK/ERK ratio while imatinib reduced this ratio only in K562 cells. 
However, the addition of HA did not inhibit the effect of imatinib on ERK phosphorylation. Moreover, in Kv562 
cells, HA, imatinib, as well as the combination of both did not modify the pERK/ERK ratio with respect to the 
baseline conditions. The biological replicates are shown in Supplementary Fig. S1.
Considering these results, we suggest that the anti-proliferative and pro-senescent effect of imatinib is abro-
gated by HA through the modulation of the PI3K/Akt pathway.
The inhibition of HA synthesis enhances the anti-proliferative and pro-senescent effect of 
imatinib. Taking into account that the combined treatment with 4MU and imatinib enhances the induction 
of senescence20, we determined if the reduction of HA levels induced by these drugs mediates those effects. For 
this purpose, both cell lines were treated with either HA, 4MU, imatinib or combinations of them. Cell growth, 
induction of senescence, and the pAkt/Akt ratio were evaluated. The 4MU concentration employed was 100 µM, 
since we had previously demonstrated that the anti-proliferative and pro-senescent effects achieved with this dose 
are fully abrogated by the addition of HA. Higher doses of 4MU proved to have effects that were independent of 
the inhibition of the HA synthesis19.
As shown in Fig. 5A, the addition of HA to cells treated with 4MU and imatinib restored cell proliferation to 
baseline levels in all cases, except for K562 cells treated with 0.5 µM imatinib, 4MU and HA, in which the differ-
ence was not statistically significant with respect to cells co-treated with 4MU and imatinib.
Figure 5B shows that the addition of HA to cells treated with imatinib and 4MU decreased the percentage 
SA-β-gal K562 and Kv562 positive cells. In K562 cells, only the co-treatment with 0.5 µM imatinib and 4MU 
induced levels of senescence (percentage of SA-β-gal positive cells) that were similar to the percentage obtained 
with each inhibitor alone. However, the addition of HA to cells treated with imatinib and 4MU reduced this per-
centage to baseline levels. Similar results were obtained for the evaluation of SAHF (see Supplementary Fig. S2).
The evaluation of the pAkt/Akt ratio (Fig. 5C) demonstrated that imatinib, 4MU and the combination of both 
decreased Akt phosphorylation to similar levels, while the addition of HA to cells treated with imatinib and 4MU 
restored the baseline phosphorylation levels in both cell lines.
Figure 1. Effect of imatinib on BCR-ABL, HA and CD44 levels. (A) K562 and Kv562 cells were treated either 
with imatinib, HA (high molecular weight) or a combination of both for 24 h. Expression levels of BCR-ABL 
were evaluated by WB. Results are expressed as: BCR-ABL index = (BCR-ABL/β-actin)treated/(BCR-ABL 
/β-actin)untreated. Data are expressed as the mean ± SEM of at least three independent experiments ##p < 0.01 
treated vs. untreated cells, ns = non-significant difference (p > 0.05) between the treatments indicated. (B) 
Levels of HA in culture supernatant were evaluated by ELISA after the treatment with either imatinib or 
4MU for 72 h. Values are expressed as the mean ± SEM (ng HA/106cells/72 h) of at least three independent 
experiments. ###p < 0.001 and ##p < 0.01, treated vs. untreated cells and **p < 0.01 between the treatments 
indicated. (C) Both cell lines were treated with imatinib for 24 h and the CD44 expression (with or without 
permeabilization) was then evaluated by FC. U937 cells were used as BCR-ABL negative control. Results are 
expressed as mean ± SEM of CD44 positive cells (%) of at least three independent experiments. ##p < 0.01, 
#p < 0.01, treated vs. untreated cells and ***p < 0.001, **p < 0.01 between the treatments indicated.
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Finally, Fig. 5D shows that the combination of 4MU and imatinib had a synergistic effect in all doses tested at 
the level of the inhibition of cell proliferation since all combination indexes (CI) were less than 1.
These results indicate that the inhibition of HA synthesis enhances the anti-proliferative and pro-senescent 
effects of imatinib.
Discussion
CML is a myeloproliferative syndrome whose first line treatment consists on BCR-ABL inhibitors such as 
imatinib, nilotinib and dasatinib. The adequate therapeutic management has significantly increased survival35. 
Imatinib is a highly effective drug; however, therapeutic failure is frequently observed due to the selection of 
resistant cells36,37. Therefore, identifying the molecules involved in imatinib resistance is crucial. In this work, we 
demonstrate for the first time that, on K562 and Kv562 CML cell lines, high molecular weight HA abrogates the 
anti-proliferative and pro-senescent effects of imatinib without modifying the apoptosis levels induced by this 
drug.
We first demonstrated that imatinib decreased BCR-ABL levels. This observation is in line with those of other 
authors, who described that imatinib induces the expression of miR-138 and miR-203, which inhibit BCR-ABL 
mRNA translation38,39. Furthermore, imatinib decreased the levels of HA and the expression of CD44 on the 
cell surface without modifying the total CD44 expression, suggesting that this receptor would be internalized. 
It is known that HYAL2, in collaboration with CD44, binds and degrades HA into smaller fragments on the 
cell surface. These fragments would then be engulfed and internalized in acidic vesicles and finally degraded by 
HYAL16,40. Considering that imatinib reduces the CD44 surface expression (without modifying the total CD44 
expression) and that it also decreases HA levels; it is proposed that this drug would enhance HA catabolism 
through the inhibition of BCR-ABL. Another mechanism that would explain the reduction of HA levels would be 
Figure 2. Evaluation of cell growth and apoptosis. (A) Both cell lines were treated with either HA (high 
molecular weight), imatinib or a combination of both. Cell growth was determined by the [3H]TdR uptake assay 
after 48 h. Results are expressed as: Cell proliferation (%) = (treated cpm × 100/untreated cpm) − 100. Results 
are expressed as means ± SEM of at least five independent experiments ###p < 0.01, ##p < 0.01 and #p < 0.05, 
treated vs. untreated cells, **p < 0.01, *p < 0.05 and ns = non-significant (p > 0.05) between the treatments 
indicated. To determine if the co-treatment of HA and imatinib abrogates the induction of apoptosis, both cell 
lines were treated with these compounds alone or in combination for 48 h and then three different parameters 
were analyzed: (B) DNA fragmentation was analyzed by fluorescence microscopy, for which K562 and Kv562 
cells were fixed with PFA and stained with DAPI. (C) Membrane asymmetry was evaluated by FC, for which 
cells were stained with annexinV-PE/7AAD after each treatment. (D) The hypodiploid content was evaluated 
by FC. For this experiment, cells were fixed with ethanol and stained with DAPI. Results are expressed as 
means ± SEM of three independent experiments ##p < 0.01 treated vs. untreated cells, #p < 0.05 treated vs. 
untreated cells, while ns = non-significant (p > 0.05) between the treatments indicated.
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the inhibition of its synthesis; since the activation of the PI3K/Akt pathway enhanced HA synthesis and imatinib 
decreased the pAkt/Akt ratio. In addition, we suggest that BCR-ABL would favor the accumulation of HA and the 
expression of CD44, since they provide a proliferative advantage (Fig. 6A). Likewise, other authors have demon-
strated that imatinib induces the degradation of the extracellular matrix, thus reducing the levels of collagen and 
heparan sulfate proteoglycans41–43. Furthermore, it has been demonstrated that imatinib reduces the production 
of HA in orbital tissue cultures44. Such effect would be mediated by the inhibition of platelet-derived growth fac-
tor receptor (PDGFR). It is noteworthy that the activation of this receptor in K562 cells leads to the differentiation 
to the megakaryocytic linage; being inactive under baseline conditions45. Recently Zhou H, et al. have reported 
that the inhibition of β-catenin and BCR-ABL decreases CD44 levels in K562 cells, in stem/progenitor cells in 
blastic crisis of CML samples as well as on in vivo models. The reduction of CD44 levels is crucial to achieve a bet-
ter therapeutic response18. Besides, it has been reported that CD44 is a leukemic stem cell marker that is crucial 
for homing and cell proliferation46. Therefore, BCR-ABL is expected to promote the expression of CD44 on the 
cell surface, while the inhibition of BCR-ABL by imatinib leads to a reduction of CD44 levels on the cell surface.
We also showed that the addition of HA abrogated the anti-proliferative and pro-senescent effects of imati-
nib without modifying the inhibitor-dependent apoptosis in both cell lines. Therefore, the induction of senes-
cence mediated by imatinib would depend on the reduction of HA levels. It is interesting that in Kv562 cells, 
2 μM imatinib induced apoptosis, but did not induce senescence; and the addition of HA did not modify the 
anti-proliferative and pro-apoptotic effects of imatinib. Therefore, HA only prevented the induction of senescence 
and this effect was observed for all doses of imatinib which were able to induce senescence in both cell lines. Thus, 
BCR-ABL would induce the accumulation of HA, which favors cell growth and prevents the induction of senes-
cence, one of the most important mechanisms of tumor suppression. The bone marrow presents high HA levels7,8. 
This microenvironment would trigger survival signaling pathways promoting imatinib resistance of CML cells. In 
addition, imatinib might reduce the accumulation of HA by Ph+ cells but could not modulate HA metabolisms 
in stromal cells (Fig. 6B). The reduction of HA levels would therefore improve the efficacy of imatinib therapy. 
Moreover, gelatinous transformation of the bone marrow has been described in patients with CML treated with 
imatinib as a late morphological change47. This transformation implies an increment in glycosaminoglycan levels, 
mainly HA, which would be involved in the therapeutic failure observed after a prolonged exposure to the drug.
The PI3K/Akt pathway is a pro-survival factor in leukemia stem cells and early committed leukemic precur-
sors. The inhibition of this pathway constitutes a therapeutic approach34. We have previously demonstrated that 
HA activates PI3K in both cell lines (K562 and Kv562)19. In this work, we demonstrated that the addition of HA 
abrogates the reduction of the pAkt/Akt ratio induced by imatinib, thus restoring the baseline ratio. Therefore, 
HA would enhance the survival of these CML cell lines, generating imatinib resistance through the activation 
of PI3K. These results are in accordance with other report demonstrating that the activation of PI3K promotes 
Figure 3. Evaluation of senescence. To determine if the combination of HA (high molecular weight) and 
imatinib prevents the induction of senescence, both cell lines were treated with either each compound alone 
or with a combination of both for 48 h. SA-β-gal and SAHF were then evaluated. (A) SA-β-gal activity (upper 
panel). Results are expressed as means ± SEM of three independent experiments ##p < 0.01 treated vs. untreated 
cells, while **p < 0.01 and *p < 0.05 between the treatments indicated (lower panel). Pictures are from a 
representative experiment (B) SAHF, magnification 400X. Arrows indicate nuclei with SAHF, while lines 
indicate nuclei with DNA fragmentation, which are characteristic of senescent and apoptotic cells, respectively.
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imatinib resistance independently of BCR-ABL mutations48 and with our previous work showing that both HA 
oligomers and Ly294002 were able to sensitize K562 and Kv562 cells to the effect of imatinib by inhibiting the 
PI3K pathway21.
Similarly, the activation of MEK/ERK favors the development of resistance to imatinib, whereas the inhibi-
tion with UO126 favors the induction of apoptosis in K562 cells49,50. Nambu et al., 2010, have described that the 
BCR-ABL-independent activation of ERK favors imatinib resistance, demonstrating that imatinib decreases the 
pERK/ERK ratio in K562 cells but not in imatinib-resistant K562 cells, which do not have a mutated BCR-ABL49. 
The effect of imatinib on the pERK/ERK ratio in K562 is in agreement with our findings. However, Yu et al., 2002, 
have reported an increase in the pERK/ERK ratio exerted by imatininb50. The difference between this study and our 
findings can be attributed to the doses of imatinib employed and by the anti-pERK antibodies used in WB assays, 
which recognize different phosphorylation sites (we evaluated the phosphorylation on Tyr204 only, while You et al. 
evaluated Thr202 and Tyr204). Our results show that HA increased ERK phosphorylation, but it did not significantly 
counteract the effect of imatinib on pERK in K562 cells. On the other hand, neither HA nor imatinib nor their com-
bination modulated ERK phosphorylation. Considering these results and those reported by Nambu et al. and Yu et 
al., the MAPK pathway would be also playing a role in the development of drug resistance in Kv562 cells.
We have previously demonstrated that 4MU and imatinib enhance the induction of senescence20. However, 
the mechanism exerted by 4MU to sensitize both cell lines to the effect of imatinib remained to be elucidated. 
In this work we demonstrated that the sensitization could be attributed to the inhibition of HA synthesis, since 
the addition of HA suppressed the effect exerted by the co-treatment of K562 and Kv562 cells with 4MU and 
imatinib. These results highlight the potential usefulness of 4MU as a co-adjuvant for the treatment of CML 
with imatinib. Moreover, in CML patients, 4MU would inhibit HA synthesis in both leukemic and stromal cells, 
improving the therapeutic response to imatinib (Fig. 6C). The microenvironment features are crucial for myeloid 
malignancies51, particularly, CML patients with bone marrow gelatinous transformation show high levels of HA 
and are prone to develop resistance to imatinib, therefore, 4MU could be a promising therapeutic alternative. In 
addition, the synergistic effect showed by the co-treatment is interesting from a therapeutic point of view, since 
the combination of both drugs would contribute to a common anti-proliferative effect through different sites of 
action. More studies are, however, needed to assert the beneficial effects of this therapy in humans.
In this work, we demonstrated for the first time that HA (high molecular weight) abrogated the 
anti-proliferative and pro-senescent effects of imatinib in K562 and Kv562 cells, suggesting an important role of 
HA in the development of imatinib resistance. Moreover, we hypothesize that the inhibition of BCR-ABL leads 
to the reduction of CD44 surface expression and HA levels, being both parameters key factors in the mechanism 
of action of imatinib.
Figure 4. Modulation of pAkt/Akt and pERK/ERK ratios. (A) K562 and Kv562 cells were treated with either 
HA (high molecular weight), Imatinib (0.5 µM for K562 cells and 2 µM for Kv562 cells) or a combination of both 
for 24 h. The phosphorylation of Akt was evaluated by WB. Results are expressed as: pAkt/Akt ratio = [(pAkt/β-
actin)/(Akt/β-actin)]treated/[(pAkt/β-actin)/(Akt/β-actin)]untreated. Results are expressed as means ± SEM 
of at least three independent experiments ##p < 0.01, #p < 0.05 treated vs. untreated cells and ** p < 0.01, 
*p < 0.05 between the treatments indicated. (B) Both cell lines were treated with either HA (high molecular 
weight), imatinib (0.5 µM for K562 cells and 2 µM for Kv562 cells) or a combination of both for 24 h. The 
phosphorylation of ERK was evaluated by WB. Results are expressed as pERK/ERK ratios. Results are expressed 
as means ± SEM of at least three independent experiments, #p < 0.05 treated vs. untreated cells, while *p < 0.05 
and ns = no significant (p > 0.05) between the treatments indicated.
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Figure 5. Effect of imatinib and the inhibition of HA synthesis on both cell lines. K562 and Kv562 cell lines 
were treated with either HA (high molecular weight), imatinib, 4MU or a combination of both. (A) Cell 
growth was determined by the [3H]TdR uptake assay for 48 h. Results are expressed as: Cell proliferation 
(%) = (treated cpm × 100/untreated cpm) − 100. Results are expressed means ± SEM of at least five 
independent experiments. (B) The induction of senescence was evaluated by the SA-β-gal activity assay. 
Results are expressed means ± SEM of at least three independent experiments. (C) The pAkt/Akt ratio was 
evaluated by WB. (D) For the inhibition of cell proliferation, the effect of 4MU and Imatinib combination 
was analyzed by effect-based strategy through Bliss independence model calculating the Combination 
Index (CI). Dotted lines represent the value of the expected additive effect calculated as: Expected 
additive effect = (4MUeffect + Imatinibeffect − 4MUeffect × Imatinibeffect) × 100 (where 0 ≤ 4MUeffect ≤ 1 and 
0 ≤ Imatinibeffect ≤ 1). The expected additive effect for 4MU + 0.25 µM Imatinib is represented by the green 
line, for 4MU + 0.5uM Imatinib is represented by the blue line and for 4MU + 2uM Imatinib is represented 
by the red line. The resulting CI was calculated as: CI = (4MUeffect + Imatinibeffect − 4MUeffect × Imatinibeffect)/
Combinationeffect. (where 0 ≤ 4MUeffect ≤ 1; 0 ≤ Imatinibeffect ≤ 1 and 0 ≤ Combinationeffect ≤ 1), being CI < 1 
synergism, CI = 1 additive and CI > 1 antagonism. All results are expressed as means ± SEM of three 
independent experiments. ###p < 0.01, ##p < 0.01 and #p < 0.05 treated vs. untreated cells, while ***p < 0.001, 
**p < 0.01, *p < 0.05 and ns = non-significant (p > 0.05) between the treatments indicated.
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Figure 6. Suggested model explaining the involvement of HA in the therapeutic failure in CML. (A) Under 
pathophysiological conditions, CML cells would have survival signals triggered by BCR-ABL and HA. The latter 
would be synthesised by stromal bone marrow cells as well as by leukemic cells. BCR-ABL would favour the 
accumulation of HA in tumor microenvironment. (B) The inhibition of BCR-ABL by imatinib would decrease 
HA levels and the expression of CD44 on the cell surface. Imatinib abrogates cell proliferation favouring 
the induction of either senescence or apoptosis. The Imatinib-induction senescence would dependent on 
the reduction of HA levels. However, bone marrow stromal cells would synthesize HA, which could trigger 
the activation of survival pathways, thus being involved in the development of imatinib resistance. (C) 
The combination of imatinib and 4MU would prevent the accumulation of HA favouring the induction of 
senescence and apoptosis, thus allowing a better therapeutic response.
9Scientific RepoRts |         (2019) 9:10930  | https://doi.org/10.1038/s41598-019-47248-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
Materials and Methods
Reagents. Recombinant high molecular weight (HMW, 1.5–1.8 × 106 Da) HA (CPN spol.s.r.o Czech 
Republic) was supplied by Farmatrade (Argentina). The Km81 anti-CD44 monoclonal Ab (MAb) was kindly 
provided by Dr. Pauline Johnson (University of British Columbia, Vancouver, Canada). bHABP, 4MU, X-gal and 
4′,6-diamidino-2-phenylindole (DAPI) were purchased from Sigma-Aldrich (USA). Drugs used were imatinib 
(Novartis, Switzerland) and vincristine (VCR, Filaxis, Argentina). Antibodies (Ab) against Abl (K-12: sc-131), 
pAkt1/2/3 (Thr308-R, sc-16646-R), Akt1/2/3 (H136, sc-8312), pERK (Tyr204-R, sc-101761), ERK (C14, sc154), 
and β-actin (C11, sc-1615), horseradish peroxidase-labeled anti-rabbit (sc-2030) and anti-goat (sc-2033) sec-
ondary antibodies, and the biotinylated anti-rat (sc-2041) secondary antibody were purchased from Santa Cruz 
Biotechnology (USA). The avidin-PE was purchased from eBioscience (USA). The [3H]TdR was purchased 
from Perkin-Elmer (Boston, USA). RPMI 1640, L-glutamine, streptomycin and penicillin were purchased from 
Invitrogen (Argentina). The Annexin-V-PE Apoptosis Detection Kit I was purchased from BD Pharmingen™ 
(BD Bioscience, USA).
Cell culture. Human CML cell lines K562 and Kv562 were grown in suspension cultures at 37 °C in a 5% CO2 
atmosphere with RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 
10 mM HEPES buffer, 5 × 10−5 M 2-mercaptoethanol, 100 µg/ml streptomycin and 100 IU/ml penicillin (RPMI-C). 
Kv562 cell line was cultured in the presence of 150 ng/ml (162 nM) VCR19. Kv562 cells have been obtained by incu-
bating K562 cells with increasing doses of VCR. In these cells, resistance developed as a result of both P-glycoprotein, 
Pgp, and PI3K over-activation19,21, with these mechanisms also being involved in imatinib resistance48,52.
Measurement of HA levels by enzyme-linked immunosorbent assay. A suspension containing 5 × 105 cells was 
grown for 72 h, as described for cell culture, in the presence of either RPMI-C alone, imatinib (0.25, 0.5 or 2 μM) 
or 4MU (500 or 100 μM). HA levels were measured in the cell supernatant by a competitive enzyme-linked immu-
nosorbent assay (ELISA), as described previously53. Briefly, 96 well microtiter plates were coated with 100 µg/mL 
HMW-HA at 4 °C. Samples and standard HMW-HA were incubated with 0.75 µg/mL bHABP at 37 °C. 
Unoccupied sites were blocked and incubated with samples at 37 °C for 4 h. The bHABP bound was determined 
with an avidin–biotin detection system. Sample concentrations were derived from a standard curve.
CD44 expression by flow cytometry. After treating cells with either RPMI-C (control) or imatinib (0.25, 
0.5 or 2 μM) for 24 h, cells were fixed with PBS plus 2% PFA for 15 min. After that, cells were permeated or not 
with PBS plus 0.2% Triton X-100 for 30 min. Cells were then blocked with phosphate-buffered saline (PBS) con-
taining 2% normal human serum for 30 min at 4 °C. After incubation, anti-CD44 Km81 was added followed by 
the addition of a biotinylated secondary Ab and Av-PE. All incubations were carried out for 1 h at 4 °C in the 
dark and with washes with cold PBS in between. Stained cells were acquired on a Pas III flow cytometer (Partec, 
Germany) and analyzed with the WinMDI 2.8 software (Scripps Institute, La Jolla)53. The corresponding isotypic 
controls were included in each assay. The ATCC U937 cell line was grown under the same conditions as described 
above and used as Ph chromosome negative control.
Cell proliferation. Cell proliferation was analyzed by the [3H]TdR uptake assay evaluated at 48 h in 96-well 
microtiter plates19. Fifty thousand cells per well (2.5 × 105 cells/ml) were used. Cells were grown at 37 °C in a 
5% CO2 atmosphere with either RPMI-C, HA (300 µg/ml) or 4MU (100 μM) or imatinib (0.25; 0.5 or 2 µM), or 
combinations of them. After pulsing with 1 μCi [3H]TdR for 6 h, cells were harvested and counted in a liquid 
scintillation counter (Beckman, MD). Results were calculated from the mean cpm of [3H]TdR incorporated in 
triplicate cultures. Untreated cells represented 100% cell survival. Cell viability at the beginning of the experiment 
was higher than 95%, as assessed by the Trypan blue dye.
Evaluation of apoptosis. Cells (5 × 105 cells/ml) were treated with either RPMI-C or HA (300 µg/ml) or 4MU 
(100 μM) or imatinib (0.25; 0.5 or 2 µM µM), or combinations of them for 48 h at 37 °C in a 5% CO2 atmosphere. 
Then, membrane asymmetry, DNA fragmentation and the hypodiploid DNA content were evaluated. For mem-
brane asymmetry, the Annexin-V-PE Apoptosis Detection Kit I (BD Biosciences, USA) was used following the 
manufacturer’s instructions. A PAS III flow cytometer (FC) (Partec, Germany) was used to acquire data, which 
were analyzed with the WinMDI 2.8 software (Scripps Institute, La Jolla, USA). For DNA fragmentation and the 
hypodiploid DNA content, cells were fixed with phosphate buffer saline (PBS) plus 2% p-formaldehyde (PFA) 
or 70% ethanol, respectively, stained with DAPI and evaluated by fluorescence microscopy (Olympus BX51, 
America Inc.) and FC (PAS III flow cytometer, Partec Germany), respectively54,55.
evaluation of senescence. Cell senescence was assessed through SA-β-gal activity and the presence 
SAHF56. For SA-β-gal, cells (5 × 105 cells/ml) were incubated with either RPMI-C, HA (300 µg/ml) or 4MU 
(100 μM) or imatinib (0.25; 0.5 or 2 µM), or combinations of them at 37 °C in a 5% CO2 atmosphere. After 48 h, 
cells were fixed with PBS plus 2% PFA and washed with PBS. Each vial was incubated for 24 h at 37 °C with 1 ml 
of staining solution (1 mg/ml X-gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl2, 
150 mM NaCl, 30 mM citric acid/phosphate pH = 6). Cells were washed twice with PBS and the SA-β-gal activity 
was evaluated in an Olympus BX51 (America Inc.) microscope. Blue cells were considered positive. For each 
condition, 200 cells were counted and the percentage of SA-β-gal positive cells was calculated25,56. For SAHF, cells 
were subjected to similar treatments. After 48 h, cells were fixed with PBS plus 2% PFA, washed and incubated 
with 1 μg/ml DAPI in PBS plus 0.2% Triton X-100 for 30 min at room temperature. Cells were analyzed by fluo-
rescence microscopy (Olympus BX51, America Inc.).
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Western blot. Cells were treated with either RPMI-C, HA (300 µg/ml) or 4MU (100 μM) or imatinib (0.5 or 
2 µM) or combinations of them for 24 h at 37 °C in a 5% CO2 atmosphere. Cells were then lysed with hypotonic buffer 
(0.02 M Tris pH = 8, 0.15 M NaCl, 0.1 M NaF, 1 mM PMSF, 10% glycerol, 1% NP-40, 20 µg/ml leupeptin, 20 µg/ml apro-
tinin, 1 mM sodium o-vanadate). After centrifugation (13000 rpm 30 min), equal amounts of protein were resolved by 
SDS-polyacrylamide gel electrophoresis and transferred onto a PVDF membrane (Osmonics Inc., Gloucester, MA). 
The membrane was blocked and incubated with specific antibodies to Abl, p-Akt, Akt, p-ERK, ERK or β-actin over-
night at 4 °C followed by incubation with a horseradish peroxidase-labeled secondary antibody for 2 h at 37 °C. The 
reaction was developed with a chemiluminescent detection system. Gel images obtained with a digital camera were 
subjected to densitometric analysis with the Image Scion Software (Scion Corporation, USA)19,57. Akt and ERK were 
evaluated after stripping on the membranes on which pAkt and pERK had previously been determined, respectively.
statistical analysis. All results were analyzed by one way-ANOVA and the Bonferroni’s test. Analyses were 
performed with the Prism software (Graph Pad, San Diego, CA, USA). P values < 0.05 were regarded as statisti-
cally significant19. The drug combination analysis was performed according to the Bliss independence model58.
Data Availability
Data generated or analyzed during this study are available from the corresponding author on reasonable request.
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